Infectious diseases specialists diagnose and treat infections from bacteria, viruses, fungi, and parasites, focusing on fevers, antibiotics, and vaccines.
Send us all your questions or requests, and our expert team will assist you.
The infecting species stratify the therapeutic management of malaria, the severity of the disease (uncomplicated vs. severe), the geographical origin of the infection (which implies likely drug resistance patterns), and the patient’s demographics (pregnancy, age, weight). The overarching goals are to rapidly eliminate the parasite from the blood to prevent progression to severe disease, to prevent transmission to the vector, and, in the case of P. vivax and P. ovale, to eradicate the dormant liver stages to avoid relapse.
For uncomplicated P. falciparum malaria, the World Health Organization (WHO) and global treatment guidelines universally recommend Artemisinin-based Combination Therapies (ACTs). This strategy employs a potent, fast-acting artemisinin derivative (such as artemether or artesunate) combined with a longer-acting partner drug (such as lumefantrine, amodiaquine, or mefloquine).
For P. vivax, P. ovale, P. malariae, and P. knowlesi, Chloroquine remains the treatment of choice in areas where these species remain sensitive. However, in regions with Chloroquine-resistant P. vivax (such as parts of Indonesia and Papua New Guinea), ACTs are the preferred alternative.
A unique challenge in managing P. vivax and P. ovale is the presence of hypnozoites—dormant liver parasites that are unaffected by blood-stage drugs such as artemisinin or chloroquine. To achieve a “radical cure” and prevent future relapses, a second drug called Primaquine (or the newer single-dose Tafenoquine) is required.
These 8-aminoquinoline drugs target the liver stage. However, they carry a significant risk for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, a common genetic enzyme disorder. In G6PD-deficient individuals, these drugs can cause severe hemolysis (destruction of red blood cells). Therefore, G6PD testing is a mandatory prerequisite before administering radical cure therapy.
Severe malaria is a medical emergency requiring admission to an intensive care unit or a high-dependency ward. The standard of care is intravenous (IV) or intramuscular Artesunate. Clinical trials have definitively proven that parenteral Artesunate reduces mortality significantly compared to the older standard, Quinine.
The emergence of antimalarial resistance is the greatest threat to malaria management. Resistance to Chloroquine and Sulfadoxine-Pyrimethamine is widespread. More concerning is the emergence of partial artemisinin resistance, first detected in the Greater Mekong Subregion and now emerging in parts of East Africa. This manifests as delayed parasite clearance.
To combat this, clinicians rely on the “Combination” aspect of ACTs. Even if the artemisinin component is slower to act, the partner drug usually clears the infection. However, if resistance develops to the partner drug as well, treatment failure occurs. This necessitates careful surveillance and the rotation of different ACT regimens based on local efficacy data.
Pediatrics: Children require weight-based dosing. They are more prone to hypoglycemia and cerebral edema, requiring vigilant monitoring of blood sugar and fluid status. Pediatric formulations of ACTs (dispersible tablets) improve adherence.
Following the clearance of the parasite, the body enters a regenerative phase. The bone marrow, previously suppressed, upregulates red blood cell production to correct anemia. This requires adequate iron stores, folate, and nutritional support. The spleen, often enlarged, slowly recedes as it processes the debris of the infection. In cases of cerebral malaria, while most survivors recover fully, some (particularly children) may require neurological rehabilitation for cognitive or motor deficits caused by the cerebral insult. Long-term follow-up is essential to monitor for post-malaria anemia and neurological sequelae.
Send us all your questions or requests, and our expert team will assist you.
ACT stands for Artemisinin-based Combination Therapy. It is the standard treatment for malaria. It combines a fast-acting drug derived from the sweet wormwood plant (artemisinin) with a longer-lasting partner drug. This combination is highly effective at killing parasites and helps prevent the malaria parasite from developing resistance to the medication.
Patients infected with P. vivax or P. ovale need a second drug (usually Primaquine or Tafenoquine) because these species can leave dormant parasites “sleeping” in the liver. The primary drugs are cleared from the blood but do not reach the liver. The second drug kills these liver parasites, preventing the disease from returning months later.
Quinine is an older drug that is still used, but it is no longer the first choice for most cases because it has more side effects (such as ringing in the ears and low blood sugar) and requires a longer treatment course than modern ACTs. It is typically reserved for the first trimester of pregnancy or when ACTs are unavailable.
Uncomplicated malaria can be treated at home with oral medications, provided the patient can swallow pills and stay hydrated. However, “severe” malaria—marked by confusion, inability to eat/drink, severe vomiting, or difficulty breathing—is a medical emergency that requires immediate hospitalization and intravenous medication.
The drugs used to kill dormant liver parasites (Primaquine/Tafenoquine) can cause dangerous destruction of red blood cells in people with a genetic condition called G6PD deficiency. Testing for this deficiency ensures that patients can safely take the medication without risking severe anemia.
Your Comparison List (you must select at least 2 packages)
